Related Experiment Video
Updated: Oct 6, 2025

Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells
Published on: June 13, 2019
Formation of Calprotectin-Derived Peptides in the Airways of Children with Cystic Fibrosis
Teagan S Edwards1, Nina Dickerhof2, Nicholas J Magon2
1Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand; teagan.edwards@otago.ac.nz.
Insights
Calprotectin oxidation by myeloperoxidase (MPO) and proteases creates peptides. These specific calprotectin peptides can serve as novel biomarkers for neutrophilic inflammation and infection in respiratory diseases.
Area of Science:
- Biochemistry and Molecular Biology
- Immunology
- Respiratory Medicine
Background:
- Calprotectin, a neutrophil-released protein, is a known inflammatory biomarker.
- Myeloperoxidase (MPO) and proteases can oxidize and degrade calprotectin, affecting its detection.
- Oxidized calprotectin yields specific peptides at inflammatory sites.
Purpose of the Study:
- To investigate the impact of MPO-derived oxidation and proteolysis on calprotectin detection.
- To identify and characterize calprotectin-derived peptides as potential biomarkers of neutrophilic inflammation and infection.
Main Methods:
- ELISA was used to assess calprotectin detection after oxidation and degradation.
- Mass spectrometry identified specific peptides from oxidized calprotectin.
- Peptide concentrations were measured in bronchoalveolar lavage fluid from children with cystic fibrosis (CF) and controls.
Main Results:
- Calprotectin detection by ELISA significantly decreased due to oxidation and degradation.
- Six calprotectin-derived peptides were identified and detected in CF patient samples.
- Several peptides correlated with MPO concentration and neutrophil elastase activity, and were elevated in CF patients with infections.
Conclusions:
- Specific calprotectin peptides are reliable indicators of MPO and protease activity during inflammation.
- These peptides show promise as biomarkers for tracking neutrophilic inflammation in respiratory diseases like cystic fibrosis and COVID-19.
Abstract:
Calprotectin is released by activated neutrophils along with myeloperoxidase (MPO) and proteases. It plays numerous roles in inflammation and infection, and is used as an inflammatory biomarker. However, calprotectin is readily oxidized by MPO-derived hypohalous acids to form covalent dimers of its S100A8 and S100A9 subunits. The dimers are susceptible to degradation by proteases. We show that detection of human calprotectin by ELISA declines markedly because of its oxidation by hypochlorous acid and subsequent degradation. Also, proteolysis liberates specific peptides from oxidized calprotectin that is present at inflammatory sites. We identified six calprotectin-derived peptides by mass spectrometry and detected them in the bronchoalveolar lavage fluid of children with cystic fibrosis (CF). We assessed the peptides as biomarkers of neutrophilic inflammation and infection. The content of the calprotectin peptide ILVI was related to calprotectin (r = 0.72, p = 0.01, n = 10). Four of the peptides were correlated with the concentration of MPO (r > 0.7, p ≤ 0.01, n = 21), while three were higher (p < 0.05) in neutrophil elastase-positive (n = 14) than -negative samples (n = 7). Also, five of the peptides were higher (p < 0.05) in the bronchoalveolar lavage fluid from children with CF with infections (n = 21) than from non-CF children without infections (n = 6). The specific peptides liberated from calprotectin will signal uncontrolled activity of proteases and MPO during inflammation. They may prove useful in tracking inflammation in respiratory diseases dominated by neutrophils, including coronavirus disease 2019.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...

